open access

Vol 14, No 2 (2018)
Case report
Published online: 2018-04-26
Get Citation

Patient with stage IV melanoma with BRAF mutation — immunotherapy or BRAF and MEK inhibitors?

Bożena Cybulska-Stopa, Marek Ziobro
DOI: 10.5603/OCP.2018.0004
·
Oncol Clin Pract 2018;14(2):100-103.

open access

Vol 14, No 2 (2018)
CASE REPORT
Published online: 2018-04-26

Abstract

Treatment of patients with non-operative or metastatic melanoma has changed. New therapies (immunotherapy, targeted therapies — BRAF/MEK inhibitors) significantly prolonged the survival of melanoma patients. The therapy sequence has not been determined, especially in the group of patients with BRAF mutation-positive melanoma. We present a case of a 44-year-old patient with BRAF mutation-positive metastatic. Due to the slow current course of the disease, normal LDH activity, lack of metastases to the central nervous system, it was decided to use nivolumab immunotherapy in the first line of treatment. After 24 weeks of treatment, a partial remission was observed. The treatment was without complications. Currently, the patient continues immunotherapy. Treatment with nivolumab in the described case proved to be effective. The decision about the choice of a particular procedure must be consistent with dynamic of cancer, the patient’s current condition and should always be discussed with the patient.

Abstract

Treatment of patients with non-operative or metastatic melanoma has changed. New therapies (immunotherapy, targeted therapies — BRAF/MEK inhibitors) significantly prolonged the survival of melanoma patients. The therapy sequence has not been determined, especially in the group of patients with BRAF mutation-positive melanoma. We present a case of a 44-year-old patient with BRAF mutation-positive metastatic. Due to the slow current course of the disease, normal LDH activity, lack of metastases to the central nervous system, it was decided to use nivolumab immunotherapy in the first line of treatment. After 24 weeks of treatment, a partial remission was observed. The treatment was without complications. Currently, the patient continues immunotherapy. Treatment with nivolumab in the described case proved to be effective. The decision about the choice of a particular procedure must be consistent with dynamic of cancer, the patient’s current condition and should always be discussed with the patient.

Get Citation

Keywords

melanoma, immunotherapy, treatment line, nivolumab

About this article
Title

Patient with stage IV melanoma with BRAF mutation — immunotherapy or BRAF and MEK inhibitors?

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 2 (2018)

Article type

Case report

Pages

100-103

Published online

2018-04-26

DOI

10.5603/OCP.2018.0004

Bibliographic record

Oncol Clin Pract 2018;14(2):100-103.

Keywords

melanoma
immunotherapy
treatment line
nivolumab

Authors

Bożena Cybulska-Stopa
Marek Ziobro

References (7)
  1. Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017; 14(8): 463–482.
  2. Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26): 2507–2516.
  3. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839): 358–365.
  4. Flaherty KT, Robert C, Hersey P, et al. METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367(2): 107–114.
  5. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367(18): 1694–1703.
  6. Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014; 120(11): 1695–1701.
  7. Long GV, Weber JS, Infante JR, et al. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016; 34(8): 871–878.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl